Company intelligence / Profile preview

BladderCell LTP

Royal Oak, Michigan, United States

Ownership: Private
Development stage: Other

Overview

BladderCell is a biotechnology company focused on developing innovative cell therapies for urological conditions, specifically targeting underactive bladder (UAB). The company's lead program, BladderCell LTP, utilizes autologous muscle-derived cells to restore bladder function in patients suffering from detrusor underactivity. By leveraging regenerative medicine techniques, BladderCell aims to provide a long-term solution for patients who currently have limited treatment options beyond catheterization. The company is currently in the pre-clinical stage, working towards advancing its therapeutic candidates into human clinical trials.

Therapeutic areas: UrologyNephrology
Modalities: Cell therapyAutologous cell therapy
Industry: Biotech

Beyond the preview

Go deeper on BladderCell LTP.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BladderCell LTP.

Explore the full profile